Jennifer Hague

Jennifer Hague

Auto-generated profile, based on publicly available information

Jennifer Hague

Department of Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2017 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
RARachel Allison
Rachel Allison
JEJames Edgar
James Edgar
GPGuy Pearson
Guy Pearson
TRTania Rizo
Tania Rizo
TNTimothy Newton
Timothy Newton
EREvan Reid
Evan Reid
Contacts between endosomes and the endoplasmic reticulum (ER) promote endosomal tubule fission, but the mechanisms involved and consequences of tubule fission failure are incompletely understood. We found that interaction between the microtubule-severing enzyme spastin and the ESCRT protein IST1 at ER–endosome contacts drives endosomal tubule fission. Failure of fission caused defective sorting of mannose 6-phosphate receptor, with consequently disrupted lysosomal enzyme trafficking and abnormal lysosomal morphology, including in mouse primary neurons and human stem cell–derived neurons. Consistent with a role for ER-mediated endosomal tubule fission in lysosome function, similar lysosomal abnormalities were seen in cellular models lacking the WASH complex component strumpellin or the ER morphogen REEP1. Mutations in spastin, strumpellin, or REEP1 cause hereditary spastic paraplegia (HSP), a disease characterized by axonal degeneration. Our results implicate failure of the ER–endosome contact process in axonopathy and suggest that coupling of ER-mediated endosomal tubule fission to lysosome function links different classes of HSP proteins, previously considered functionally distinct, into a unifying pathway for axonal degeneration.

1 August 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MTMarc Tischkowitz
Marc Tischkowitz
SHSidong Huang
Sidong Huang
SBSusana Banerjee
Susana Banerjee
JHJennifer Hague
Jennifer Hague
WHWilliam P. D. Hendricks
William P. D. Hendricks
BWBernard E. Weissman
Bernard E. Weissman
Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare and highly aggressive ovarian malignancy. In almost all cases, it is associated with somatic and often germline pathogenic variants in SMARCA4, which encodes for the SMARCA4 protein (BRG1), a subunit of the SWI/SNF chromatin remodeling complex. Approximately 20% of human cancers possess pathogenic variants in at least one SWI/SNF subunit. Because of their role in regulating many important cellular processes including transcriptional control, DNA repair, differentiation, cell division, and DNA replication, SWI/SNF complexes with mutant subunits are thought to contribute to cancer initiation and progression. Fewer than 500 cases of SCCOHT have been reported in the literature and approximately 60% are associated with hypercalcemia. SCCOHT primarily affects females under 40 years of age who usually present with symptoms related to a pelvic mass. SCCOHT is an aggressive cancer, with long-term survival rates of 30% in early-stage cases. Although various treatment approaches have been proposed, there is no consensus on surveillance and therapeutic strategy. An international group of multidisciplinary clinicians and researchers recently formed the International SCCOHT Consortium to evaluate current knowledge and propose consensus surveillance and therapeutic recommendations, with the aim of improving outcomes. Here, we present an overview of the genetics of this cancer, provide updates on new treatment targets, and propose management guidelines for this challenging cancer.

19 March 2019 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
JHJennifer Hague
Jennifer Hague
PTPhilip Twiss
Philip Twiss
ZMZoe Mead
Zoe Mead
SPSoo-Mi Park
Soo-Mi Park
Classical Cornelia de Lange syndrome (CdLS) is a rare genetic disorder which is associated with distinctive facial features, growth retardation, significant intellectual disability and global developmental delay, hirsutism, and upper-limb reduction defects. Classical CdLS is associated with pathogenic variants in NIPBL. We present a clinical diagnosis of classical CdLS made in a second trimester male fetus with advanced maceration who had undergone intrauterine death at 15 + 6 weeks gestation. The diagnosis was suspected after multiple congenital anomalies were identified on fetal postmortem examination. These included intrauterine growth retardation, upper limb anomalies, ventricular septal defect and diaphragmatic hernia, and skeletal and genitourinary abnormalities. Related prenatal screening findings included a raised nuchal translucency and low maternal serum pregnancy-associated plasma protein-A. Targeted molecular sequencing of genes associated with CdLS identified a novel de novo frameshift pathogenic variant in NIPBL, which confirmed the diagnosis. This report describes our case and reviews the current literature on prenatal diagnosis of CdLS. In summary, we demonstrate that clinical diagnosis of CdLS in a second trimester fetus, through postmortem examination findings, is possible, with confirmation through molecular testing.

21 March 2016 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
JHJennifer Hague
Jennifer Hague
IDIsabelle Delon
Isabelle Delon
KBKim Brugger
Kim Brugger
HMHoward Martin
Howard Martin
SAStephen Abbs
Stephen Abbs
SPSoo‐Mi Park
Soo‐Mi Park

12 May 2017 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
JHJennifer Hague
Jennifer Hague
IDIsabelle Delon
Isabelle Delon
KBKim Brugger
Kim Brugger
HMHoward Martin
Howard Martin
LSLeanne Sparnon
Leanne Sparnon
SPSoo‐Mi Park
Soo‐Mi Park

23 February 2017 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
JHJennifer Hague
Jennifer Hague
GHGerald Hackett
Gerald Hackett
CACarlo Acerini
Carlo Acerini
SPSoo‐Mi Park
Soo‐Mi Park